Milk Thistle / Silymarin (Silybum marianum)
Silybum marianum seed flavonolignans (silymarin complex; silybin A+B the major active fraction). Silybin activates Nrf2 → ↑GSH, SOD, catalase in hepatocytes; inhibits NF-κB → ↓TNF-α, IL-6, IL-1β from Kupffer cells; suppresses TGF-β/SMAD2/3 → reduced stellate cell activation and hepatic fibrosis; blocks HCV NS5B RNA polymerase in vitro. IV silybin (Legalon SIL) is standard of care for Amanita phalloides poisoning via OATP1B1/1B3 inhibition, interrupting enterohepatic toxin recirculation. Poor oral bioavailability (20–50%) substantially improved by phytosome formulation (3–5×).
Overview
Silybum marianum (family Asteraceae, tribe Cynareae) is a biennial or annual thistle native to the Mediterranean basin, widely naturalised worldwide. The pharmacologically active material is extracted from the dried seeds (achenes), which contain the flavonolignan complex silymarin. The common name derives from the white marbling on its leaves, traditionally attributed to drops of the Virgin Mary's milk — hence the alternative name "Marian thistle." Since antiquity — Dioscorides (1st century CE) and Gerard's Herbal (1597) — it has been used specifically for liver and biliary disorders, a traditional use now supported by substantial mechanistic and clinical evidence.
The standardised extract (70–80% silymarin from seed) contains silybin A and silybin B (~50–60%; most pharmacologically active; also called silibinin), silychristin (~20%), silydianin (~10%), and minor isosilybins. Flavonolignans are formed biosynthetically by peroxidase-catalysed coupling of taxifolin with coniferyl alcohol. Bioavailability is the critical limitation: approximately 20–50% of flavonolignans are absorbed orally, further limited by first-pass metabolism and biliary excretion. The Phytosome formulation (silybin-phosphatidylcholine complex, IdB 1016) improves bioavailability 3–5 fold via phospholipid-mediated intestinal membrane partitioning.
Milk thistle is approved as a prescription medicine in Germany (Legalon) for liver disease and is available OTC globally. With over 3,000 peer-reviewed publications it is one of the most researched hepatoprotective botanicals. The IV formulation (Legalon SIL) is the only pharmacological treatment with robust evidence for Amanita phalloides poisoning — considered standard of care in European poison centres.
Mechanism of Action
Nrf2 / Keap1 Activation — Hepatocyte Antioxidant Defence
Silybin (phenolic hydroxyl groups)
│
▼
Cysteine thiol modification on Keap1 (Cys273, Cys288)
[Keap1 normally anchors Nrf2 for ubiquitin degradation]
│
▼
Keap1 releases Nrf2 → nuclear translocation
│
▼
Nrf2 / sMaf heterodimer binds ARE elements
│
├── GCL ↑ → ↑ Glutathione (GSH) synthesis
├── SOD1/2 ↑ → superoxide dismutation → H₂O₂
├── Catalase ↑ → H₂O₂ → H₂O + O₂
├── HO-1 ↑ → anti-inflammatory cytoprotection
└── NQO1 ↑ → quinone reduction / detoxification
- Keap1 modification: Silybin's phenolic hydroxyl groups react with critical cysteine thiols on Keap1 — the cytosolic anchor that normally tags Nrf2 for ubiquitin-mediated proteasomal degradation
- Nrf2 nuclear entry: Released Nrf2 translocates to nucleus and heterodimerises with small Maf proteins, binding Antioxidant Response Elements (AREs) in target gene promoters
- Antioxidant gene cascade: GCL (↑GSH), SOD1/2, catalase, HO-1, NQO1 — comprehensive upregulation reduces ROS-mediated lipid peroxidation, protein carbonylation, and DNA oxidation in hepatocytes under alcoholic, metabolic, or toxic injury
- NF-κB suppression (anti-inflammatory): Silybin inhibits IKKβ → prevents IκBα degradation → NF-κB p65/p50 retained in cytoplasm → reduced TNF-α, IL-1β, IL-6, IL-8, COX-2, MMP-9 transcription in Kupffer cells and macrophages
- TGF-β/SMAD anti-fibrotic cascade: Silybin reduces TGF-β1 expression, inhibits SMAD2/3 phosphorylation, directly suppresses hepatic stellate cell (HSC) activation via reduced PDGF signalling and ↑PPARγ expression → reduced collagen I/III deposition and favoured ECM degradation
Pleiotropic Mechanisms
OATP Inhibition — Amanita Rescue
IV silybin competitively inhibits OATP1B1/1B3 in hepatocyte basolateral membranes — the same transporters responsible for hepatic uptake of amanitin from portal blood — interrupting enterohepatic recirculation and dramatically reducing hepatocyte amanitin exposure
HCV NS5B Polymerase Inhibition
Silybin competitively inhibits the HCV RNA-dependent RNA polymerase (NS5B) at the active site (IC50 low micromolar in enzymatic assays); clinically relevant only via IV administration — oral bioavailability is insufficient to reach hepatic concentrations needed for viral suppression
HSC Quiescence — Anti-fibrotic
↑PPARγ expression in hepatic stellate cells promotes quiescent phenotype; combined with SMAD pathway suppression, ↑MMP activity, and ↓TIMP-1 → net balance shifts toward ECM degradation over collagen deposition in chronic liver disease
Mast Cell and Kupffer Cell Inhibition
Silymarin inhibits mast cell degranulation → reduced histamine and leukotriene release in hepatic sinusoidal space; combined NF-κB suppression in Kupffer cells produces mutually reinforcing hepatic anti-inflammatory effect
Clinical Use & Dosing
| Indication | Evidence Level | Dose / Formulation | Duration |
|---|---|---|---|
| Alcoholic liver disease | Low-Moderate | Silymarin 420–600 mg/day (LI 132 standardised) | 6 months – 2 years |
| NAFLD / NASH | Low-Moderate | Silymarin 140–420 mg/day; phytosome preferred for hepatocyte delivery | 8–24 weeks |
| Chronic hepatitis C (adjunctive) | Low (oral) / Moderate (IV) | 420–600 mg/day oral OR IV silybin (Legalon SIL) | Variable |
| Amanita phalloides poisoning | Standard of Care | IV silybin 20 mg/kg/day (Legalon SIL) | Until recovery; must start within 24–48 h of ingestion |
| Drug-induced liver injury (DILI) | Low | Silymarin 420 mg/day | 8 weeks |
Standard oral dose: 70–80% silymarin content at 140 mg three times daily (420 mg/day). Phytosome formulation (IdB 1016: 80 mg silybin-phosphatidylcholine twice daily) is bioequivalent to 420 mg standard silymarin with substantially better hepatocyte delivery.
Key Studies
| Study | Design / n | Key Result |
|---|---|---|
| Rambaldi, Jacobs, Gluud (2005) Cochrane Database Syst Rev |
Systematic review, 13 RCTs, n=915; alcoholic liver disease and/or hepatitis B/C | Liver-related mortality: RR 0.50 (95% CI: 0.22–1.13) — trend toward benefit but not statistically significant; concluded insufficient evidence; high risk of bias in included trials; call for larger high-quality RCTs |
| Saller et al. (2008) Forsch Komplementmed |
Updated systematic review; broader liver disease spectrum including NAFLD/NASH | ALT normalisation OR ~2.5–3.0 vs placebo in NAFLD; hepatic fat fraction reduction on ultrasound; HOMA-IR reduction; NAS score improvement in one adequately powered trial |
| Hruby et al. (1983) Retrospective cohort, Amanita poisoning |
Retrospective cohort; IV silybin vs historical controls; A. phalloides poisoning (n not specified, Austrian series) | Mortality reduced from ~30% historical baseline to 12.8% with IV silybin; no RCT possible (ethical); OATP inhibition mechanism biochemically well-characterised, directly explaining clinical benefit |
Key Insight — The Bioavailability Paradox: The gap between silymarin's potent in vitro and mechanistic efficacy and its inconsistent oral clinical trial results is primarily explained by poor oral bioavailability. IV silybin achieves hepatic concentrations sufficient for OATP inhibition (Amanita rescue) and HCV NS5B inhibition that oral dosing cannot reach. The phytosome formulation substantially narrows this gap for hepatoprotective use. The strongest clinical evidence — Amanita poisoning — is precisely the indication where the bioavailability problem is bypassed entirely through IV administration, allowing the full OATP-mediated mechanism to operate.
Safety & Drug Interactions
- Adverse effects: GI symptoms (mild, dose-related): nausea, loose stools, mild diarrhoea; occasional headache; rare allergic reactions — cross-reactivity with Asteraceae family; contraindicated in ragweed allergy
- CYP2C9 inhibition (in vitro; low clinical significance): Silybin inhibits CYP2C9 in vitro; one RCT showed no significant effect on warfarin pharmacokinetics at standard oral doses; clinical significance at therapeutic doses considered low-to-negligible
- OATP substrate drugs (IV silybin only): High-dose IV silybin could theoretically reduce hepatic uptake of OATP substrates (statins, some antibiotics) at doses used in Amanita treatment; no clinically documented adverse interaction reported
- UGT inhibition (in vitro): Silymarin inhibits UGT enzymes in vitro → potential interactions with heavily glucuronidated drugs (irinotecan); clinical significance uncertain; monitor in oncology patients receiving irinotecan-based regimens
- Overall interaction profile: Widely considered one of the safest botanical medicines with the lowest drug interaction risk of any commonly used hepatoprotective herb — a preferred herbal choice for patients on complex medication regimens
- Pregnancy: Insufficient data for oral silymarin; generally considered low risk at standard doses; avoid high-dose IV silybin in pregnancy except for life-threatening Amanita poisoning (where risk-benefit clearly favours treatment)
- Long-term safety: Up to 41 months studied in alcoholic liver disease trials without emergence of new safety signals; Legalon SIL has been used in European clinical practice for decades
References
- Rambaldi A, Jacobs RL, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2005;(2):CD003620. doi:10.1002/14651858.CD003620.pub2
- Saller R, Melzer J, Reichling J, et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed. 2008;15(1):9-20. doi:10.1159/000113648
- Hruby K, Csomos G, Fuhrmann M, Thaler H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol. 1983;2(2):183-95.
- Giorgi VS, Vieira JL, et al. Silymarin effects on non-alcoholic fatty liver disease: a systematic review. J Gastrointestin Liver Dis. 2021;30(1):101-7.
- Evans WC. Trease and Evans' Pharmacognosy. 16th ed. Saunders; 2009.